Treating Cancer with uPAR Inhibitors

**DESCRIPTION**
Increasing evidence suggests that a subpopulation of cancer cells, referred to as cancer stem cells, exhibit an increased potential for malignancy and invasiveness. It has been hypothesized that cancer stem cells may act as a “reservoir” of highly tumorigenic cells and thus serve as an underlying cause of tumor recurrence and metastasis for a number of cancers.

Cancer stem cells have been shown to express high levels of the signaling receptor, uPAR, which is thought to promote cell survival and migration. Inhibition of uPAR represents a powerful approach to target and eradicate cancer stem cells from the body.

This patent application broadly covers methods for treating cancer by administering novel uPAR inhibitors, predicting outcome of disease by measuring uPAR expression and isolating cancer stem cells by sorting on uPAR-positive tumor cells.

**KEY ASPECTS**
- Novel therapeutic approach for treatment of drug-resistant malignancies
- Inhibition of metastasis for highly aggressive tumors
- Applicable for treating solid, systemic or circulating tumors
- uPAR expression is useful for predicting severity and outcome of cancer

**INTELLECTUAL PROPERTY**

<table>
<thead>
<tr>
<th>Title</th>
<th>US Application Number</th>
<th>Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification and Characterization of Cancer Stem Cells and Methods of Use</td>
<td>12/768,607</td>
<td>4/27/2010</td>
</tr>
</tbody>
</table>

**CONTACT**
Ryan Kelly, Ph.D.
Manager, Office of Technology Licensing
Telephone: (626) 471 9359 | Email: rykelly@coh.org

This material is a summary of public domain and non-confidential City of Hope information. Additional material may be disclosed under a confidentiality agreement.

MK-004